| ARGENX SE EO -,10 |
| Niederlande |
| Gesundheit |
| NL0010832176 / A11602 |
| 1AE (Frankfurt) |
| FRA:1AE, ETR:1AE, 1AE:GR |
| EuroStoxx50 |
| https://www.argenx.com/ |
|
argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies ..
>Volltext.. |
| 43583.14 Mio. EUR |
| 40270.31 Mio. EUR |
| 2805.01 Mio. EUR |
| 380.38 Mio. EUR |
| 1180.04 Mio. EUR |
| 19.6 EUR |
| 36.78 Mio. EUR |
| 1777.98 Mio. EUR |
| 495.09 Mio. EUR |
| 3.77 |
| 87.66% |
| - |
| - |
| - |
| - |
| - |
| ARGENX, ARGEN-X, ARGEN X |
| 26.02.26 |
|
||||
|